Market Cap | 791.91M | P/E | - | EPS this Y | 27.10% | Ern Qtrly Grth | - |
Income | -228.06M | Forward P/E | -3.75 | EPS next Y | -8.00% | 50D Avg Chg | -21.00% |
Sales | 288k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -31.00% |
Dividend | N/A | Price/Book | 3.67 | EPS next 5Y | - | 52W High Chg | -53.00% |
Recommedations | 1.60 | Quick Ratio | 15.54 | Shares Outstanding | 76.36M | 52W Low Chg | 38.00% |
Insider Own | 0.01% | ROA | -33.45% | Shares Float | 57.33M | Beta | 1.07 |
Inst Own | 94.99% | ROE | -53.97% | Shares Shorted/Prior | 10.46M/8M | Price | 18.36 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 796,129 | Target Price | 39.56 |
Oper. Margin | -100,259.72% | Earnings Date | Nov 11 | Volume | 500,040 | Change | -1.55% |
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
BTIG | Buy | Sep 26, 24 |
RBC Capital | Outperform | Sep 19, 24 |
RBC Capital | Outperform | Sep 13, 24 |
Goldman Sachs | Buy | Sep 12, 24 |
Needham | Buy | Sep 11, 24 |
HC Wainwright & Co. | Buy | Sep 10, 24 |
BTIG | Buy | Sep 10, 24 |
Needham | Buy | Aug 30, 24 |
RBC Capital | Outperform | Aug 28, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Fairmount Funds Management LLC | Director Director | Jan 22 | Buy | 21.00 | 476,190 | 9,999,990 | 1,839,954 | 01/24/24 |
Meisner Lara | Chief Legal Officer Chief Legal Officer | Jun 02 | Sell | 24.75 | 7,500 | 185,625 | 29,971 | 06/06/23 |
Meisner Lara | Chief Legal Officer Chief Legal Officer | Jun 02 | Option | 17.01 | 7,500 | 127,575 | 35,097 | 06/06/23 |
Myers Scott Dunseth | Chief Executive Offi.. Chief Executive Officer | Apr 12 | Buy | 25.3697 | 4,000 | 101,479 | 259,500 | 04/12/23 |
Meisner Lara | General Counsel and.. General Counsel and Secretary | Mar 09 | Sell | 29.07 | 29,971 | 871,257 | 03/10/23 | |
Violin Jonathan | Chief Executive Off.. Chief Executive Officer | Feb 02 | Sell | 36.8 | 50,000 | 1,840,000 | 480,905 | 02/07/23 |
Violin Jonathan | Chief Executive Off.. Chief Executive Officer | Feb 02 | Option | 0.15 | 50,000 | 7,500 | 530,905 | 02/07/23 |
Meisner Lara | General Counsel and.. General Counsel and Secretary | Jan 23 | Sell | 35.66 | 6,843 | 244,021 | 01/25/23 | |
Meisner Lara | General Counsel and.. General Counsel and Secretary | Jan 23 | Option | 18.52 | 6,843 | 126,732 | 6,843 | 01/25/23 |
Katz Barrett | Chief Medical Office.. Chief Medical Officer | Jan 13 | Sell | 37.11 | 29,000 | 1,076,190 | 01/18/23 | |
Katz Barrett | Chief Medical Office.. Chief Medical Officer | Jan 13 | Option | 23.03 | 29,000 | 667,870 | 24,853 | 01/18/23 |
Katz Barrett | Chief Medical Office.. Chief Medical Officer | Jan 09 | Sell | 34.17 | 60,000 | 2,050,200 | 01/11/23 | |
Katz Barrett | Chief Medical Office.. Chief Medical Officer | Jan 09 | Option | 23.03 | 60,000 | 1,381,800 | 47,377 | 01/11/23 |
Meisner Lara | General Counsel and.. General Counsel and Secretary | Dec 15 | Option | 23.03 | 1,597 | 36,779 | 1,297 | 12/19/22 |
Meisner Lara | General Counsel and.. General Counsel and Secretary | Dec 15 | Sell | 28.26 | 1,597 | 45,131 | 12/19/22 | |
Meisner Lara | General Counsel and.. General Counsel and Secretary | Dec 12 | Option | 23.03 | 16,256 | 374,376 | 15,656 | 12/14/22 |
Meisner Lara | General Counsel and.. General Counsel and Secretary | Dec 12 | Sell | 28.09 | 16,256 | 456,631 | 12/14/22 | |
Fairmount Funds Management LLC | - - | Aug 17 | Buy | 23.50 | 425,531 | 9,999,978 | 1,363,764 | 08/19/22 |
Violin Jonathan | Chief Executive Off.. Chief Executive Officer | Jun 01 | Sell | 12.20 | 30,000 | 366,000 | 480,905 | 06/02/22 |
Violin Jonathan | Chief Executive Offi.. Chief Executive Officer | May 02 | Sell | 13.04 | 30,000 | 391,200 | 510,905 | 05/04/22 |
Violin Jonathan | Chief Executive Off.. Chief Executive Officer | Apr 01 | Sell | 18.93 | 30,000 | 567,900 | 540,905 | 04/05/22 |
Violin Jonathan | Chief Executive Off.. Chief Executive Officer | Feb 01 | Sell | 19.06 | 30,000 | 571,800 | 600,905 | 02/03/22 |